Elan Drug Technologies

Navigation

• Home
• Careers
• Sitemap

IPDAS® Controlled Release Technology

The Intestinal Protective Drug Absorption System (IPDAS^® Technology) is a high density multiparticulate controlled release tablet technology, designed for use with more gastrointestinal irritant compounds.

Benefits offered by the IPDAS^® Technology include:

• high density multiparticulate formulation
• gastrointestinal protection for more locally irritant drugs (e.g. NSAIDs)
• advantages of multiparticulate in a tablet form
• fast onset if required   

IPDAS^®, Intestinal Protective Drug Absorption System, was initially designed as part of the development process for Elan Drug Technologies’ proprietary naproxen formulation, Naprelan^®. The objective was to develop a once daily controlled release system that would have a fast onset of action and reduced gastric irritancy. That objective was achieved in Naprelan^®; it has a proven onset of pain relief within 30 minutes that lasts up to 24 hours and has been shown to be well-tolerated. IPDAS^® delivery system can also be employed to confer the advantages of multiparticulate technology, in a tablet dosage form. The IPDAS^® technology is composed of numerous high density controlled release beads, which are compressed into a tablet form.

As each candidate drug presents itself with different physicochemical properties, the composition of the polymer membrane may differ for each individual IPDAS^® formulation. Varying the nature and combination of polymers within a semi-permeable membrane enables Elan Drug Technologies to achieve varying degrees of released profiles depending upon the required product profile.

Once an IPDAS^® tablet is ingested, it disintegrates and disperses beads containing a drug in the stomach, which subsequently pass into the duodenum and along the gastrointestinal tract in a controlled and gradual manner, independent of the feeding state.

Release of active ingredient is controlled by the polymer system used to coat the beads and/or the micromatrix of polymer/active ingredient formed in the extruded/spheronised multiparticulates. The intestinal protection of IPDAS^® technology is by virtue of the multiparticulate nature of the formulation, which ensures wide dispersion of irritant drug throughout the gastrointestinal tract.

Naprelan^®, which is marketed in the U.S. and Canada, employs the IPDAS^® technology. This innovative formulation of naproxen sodium is a unique controlled release formulation indicated for a variety of acute and chronic pain conditions.